Personalised mRNA melanoma vaccine expected to secure approval next year
A bespoke mRNA vaccine designed to target an individual's unique skin cancer mutations is expected to gain approval in the US, Europe, and the UK next year.
HEROIC BREAKING NEWS, written by our newsroom0 views
A personalised mRNA vaccine for melanoma is expected to be approved for use in the United States, Europe, and the United Kingdom next year, New Scientist reported. The vaccine targets the deadliest form of skin cancer by stimulating immune responses against genetic mutations that are unique to an individual patient. [1]
When used alongside standard treatment in a late-stage trial, the bespoke vaccine substantially cut the risk of cancer recurrence or death within the following two years, according to New Scientist. Alan Melcher stated that approval could happen quickly, making a decision next year reasonable. [1]
As HEROIC BREAKING NEWS reported earlier, an Australian-led phase three trial combined the personalised mRNA vaccine with a post-surgery immunotherapy drug. Professor Georgina Long served as the principal investigator on the trial, which significantly lowered the risk of melanoma recurrence and skin cancer-related death. [3]
Merck and Company is an American multinational pharmaceutical company based in Rahway, New Jersey, which operates as Merck Sharp and Dohme outside the United States and Canada. [2]
In short
- A personalised mRNA melanoma vaccine is expected to gain approval in the US, Europe, and the UK next year.
- The bespoke vaccine stimulates immune responses against unique genetic mutations in a patient's cancer.
- Combined with standard immunotherapy in a late-stage trial, the vaccine significantly cut recurrence and death rates over two years.
- Professor Georgina Long served as principal investigator on the phase three trial.
Sources
Every paragraph above points to the numbered items it rests on. Read the originals here.
- [1]Personalised cancer vaccine expected to be approved next yearNew Scientist, 3d ago (the report this story comes from)
Background
- [2]Merck & Co. on Wikipedia
- [3]Australian led trial shows mRNA vaccine lowers melanoma recurrence and death HEROIC BREAKING NEWS, 4d ago
Our newsroom writes these reports with the help of software, from the 3 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.
Related from HEROIC BREAKING NEWS
Earlier reports of ours on the same people and subjects.
- Australian led trial shows mRNA vaccine lowers melanoma recurrence and deathMedical Breakthroughs, 4d ago
- Personalized mRNA Vaccine Cuts Melanoma Recurrence Risk in Phase 3 TrialMedical Breakthroughs, 1d ago
- Cancer survivor raises awareness using custom soccer themed prosthetic eyeHumanitarian Tech, 10d ago
More in Medical Breakthroughs
- Heart Foundation invests 14 point 5 million dollars in Australian research10m ago
- Mayo Clinic researchers uncover new strategies to target aging zombie cells1h ago
- Scientists discover anti inflammatory drugs may aid virus spread1h ago
- Artificial intelligence model detects early pancreatic cancer signs before conventional scans22h ago
- Biological computer created from living cells controls a robotic dog23h ago
- Scientists record magnetic skyrmion vortices to advance brain like computing1d ago
Get the day in one email
Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.
Comments
Loading
Join the conversation
Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.
Already on the list? Enter the same address and we will send a sign-in link.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.